期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

抗肿瘤坏死因子单克隆抗体临床应用新进展 被引量：6

Recent Progress in Clinical Application of Anti-TNF Antibody McAb
下载PDF
导出
摘要 Infliximab是一直接针对肿瘤坏死因子α(TNF-α)的嵌合性单克隆抗体,主要用于治疗克罗恩病及类风湿性关节炎。随着对其研究的加深,Infliximab在临床上的应用越来越广泛。本文就in-fliximab临床应用的进展作一综述。 Infliximab, an anti-TNF-αchimeric monoclonal antibody, is primarily used in the treatment for Crehn＇s disease and rheumatoid arthritis. Infliximab is widely used in clinic and beyond its original purposes after extensive investigation on this antibody. The recent progress of Infliximab used in clinic is reviewed in this paper.
作者 苏倩波 黄赞松 唐国都
机构地区 广西医科大学第一附属医院消化内科 右江民族医学院附属医院消化内科
出处 《医学综述》 2006年第5期293-295,共3页 Medical Recapitulate
关键词 INFLIXIMAB 肿瘤坏死因子Α 单克隆抗体 Infliximab Tumor necrosing factor-α Monoclonal antibody
分类号 R969 [医药卫生—药理学]
  • 相关文献

参考文献19

  • 1Siegel SA, Shealy DJ, Nakada MT, et al. The mouse/human chimeric monoclonal antibody cA2 neutralizes TNF in vitro and protects transgenie mice from cachexia and TNF lethality in vivo [ J ]. Cytokine,1995,7( 1 ) : 15-25.
  • 2郑家驹.抗肿瘤坏死因子单克隆抗体治疗Crohn病进展[J].国外医学（消化系疾病分册）,1999,19(4):209-211. 被引量：6
  • 3Derkx B, Taminiau J, Radema S, et al. Tumour-necrosis-factor antibody treatment in Crohn's disease[ J]. Lancet, 1993,342 (8864) : 173-174.
  • 4Hyams JS, Markowitz J, Wyllie R. Use of infliximab in the treatment of Crohn's disease in children and adolescents[J]. J Pediatr, 2000, 137(2) :192-196.
  • 5Targan SR, Hanauer SB, vail Deventer S, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor a for Crohn's disease[J]. N Engl J Med, 1997,337(15) : 1029-1035.
  • 6Farrell RJ, Lodhavia PI, Alsahli M, et al. Infliximab therapy in 100 Crohn's disease patients: adverse events and clinical efficacy [ J ]. Gastroenterology,2000, 118[Suppl 2] :A5664.
  • 7Cohen RD. Infliximab as first-line therapy for severe Crohn's disease ?[ J]. Inflamm Bowel Dis, 2002.8( 1 ) : 58-59.
  • 8Greenberg GR. Infliximab as first-line therapy for Crohn's disease is premature [ J ]. Inflamm Bowel Dis, 2002,8 ( 1 ) : 60-62.
  • 9Oruc N, Ozutemiz AO, Yukselen V, et al. Infliximab : a new therapeutic agent in acute pancreatitis? [ J ]. Pancreas, 2004,28 ( 1 ) : e1-e8.
  • 10Chey WY. Infliximab for patients with refractory ulcerative colitis[ J ].Inflamm Bowel Dis, 2001,7 [ Supp 11 ] : S30-33.

二级参考文献15

  • 1Hanauer SB. Safety of infliximab in clinical trials. Pharmacol Ther, 1999, 13: 16-22.
  • 2La Duca JR, Gaspari AA. Targeting tumor necrosis factor alpha.Dermatol Clin, 2001, 19: 617-635.
  • 3O'Quinn RP, Miller JL. The effectiveness of tumor necrosis factor alpha antibody (infliximab) in treating recalcitrant psoriasis: a report of 2 cases. Arch Dermatol, 2002, 138: 644-648.
  • 4Newland MR, Weinstein A, Kerdel F. Rapid response to inflixmab in severe pustular psoriasis, von Zumbusch type. Int J Dermatol, 2002, 41: 449-452.
  • 5Devos SA, van Den Bossche N, De Vos M, et al. Adverse skin reactions to anti-TNF-alpha monoclonal antibody therapy. Dermatology. 2003. 206: 388-390.
  • 6Hanauer SB, Rutgeerts PJ, D' Haens G, et al. Delayed hypersensitivity to infliximab (remicade): re-infusion after 2-4 year interval without treatment. Gastroenterology, 1999, 116:A731.
  • 7Vergara G, Silvestre JF, Betlloch I, et al. Cutaneous drug eruption to infliximab: report of 4 cases with an interface dermatitis pattern. Arch Dermatol, 2002, 138: 1258-1259.
  • 8Wright RC. Atopic dermatitis-like eruption precipitated by infliximab. J Am Acad Dermatol, 2003, 49: 160-161.
  • 9Wang LC, Medenica MM, Shea CR, et al. Infliximab-induced eczematoid-like purpura of doucas and kapetenakis. J Am Acad Dermatol, 2003, 49: 157-158.
  • 10Verea MM, Del Pozo J, Yebra:-Pimentel MT, et al. Psoriasiform eruption induced by infliximab. Ann Pharmacother, 2004, 38:54-57.

共引文献18

同被引文献42

引证文献6

二级引证文献20

医学综述
2006年 第5期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部